Skip to main content
SpringerLink
Log in

When Are Type 1 Diabetic Patients at Risk for Cardiovascular Disease?

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

This discussion of increased cardiovascular risk in patients with type 1 diabetes reviews recent data concerning glycemia and the role of glycemic control in type 1 diabetes, as well as observations of an association with haptoglobin genotype and coronary artery disease events. This genetic predisposition also leads to oxidative damage and appears to be associated with profound high-density lipoprotein dysfunction. This article also briefly discusses recent data on general cardiovascular risk factors and provides updated comments concerning the association of coronary artery disease with other diabetes complications, especially renal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:• Of importance•• Of major importance

  1. Orchard TJ, Costacou T, Kretowski A, Nesto RW: Type 1 diabetes and coronary artery disease. Diabetes Care 2006, 29:2528–2538.

    Article  PubMed  Google Scholar 

  2. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T: Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without nephropathy: incidence and risk factors. Diabetologia 1987, 30:144–148.

    Article  CAS  PubMed  Google Scholar 

  3. Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643–2653.

    Article  PubMed  Google Scholar 

  4. Averill MM, Bornfeldt KE: Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. Curr Diab Rep 2009, 9:18–25.

    Article  CAS  PubMed  Google Scholar 

  5. • Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, et al.: Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 2009, 169:1307–1316. This paper describes the improved long-term cumulative risk of major diabetes complications after intensive therapy and compares DCCT conventional treatment results with those seen in the Pittsburgh EDC study.

    Article  PubMed  Google Scholar 

  6. Prince CT, Becker DJ, Costacou T, et al.: Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 2007, 50:2280–2288.

    Article  CAS  PubMed  Google Scholar 

  7. Pambianco G, Costacou T, Ellis D, et al.: The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006, 55:1463–1469.

    Article  CAS  PubMed  Google Scholar 

  8. Levy AP, Hochberg I, Jablonski K, et al.: Haptoglobin genotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J Am Coll Cardiol 2002, 40:1984–1990.

    Article  PubMed  Google Scholar 

  9. Suleiman M, Aronson D, Asleh R, et al.: Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 2005, 54:2802–2806.

    Article  CAS  PubMed  Google Scholar 

  10. Roguin A, Koch W, Kastrati A, et al.: Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 2003, 26:2628–2631.

    Article  PubMed  Google Scholar 

  11. Levy AP, Gerstein HC, Miller-Lotan R, et al.: The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004, 27:2767.

    Article  PubMed  Google Scholar 

  12. •• Milman U, Blum S, Shapira C, et al.: Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008, 28:341–347. This randomized clinical trial demonstrated more than a 50% reduction in cardiovascular events with vitamin E supplementation among individuals with the susceptible Hp 2-2 genotype.

    Article  CAS  PubMed  Google Scholar 

  13. Bowman BH, Kurosky A: Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 1982, 12:189–261.

    CAS  PubMed  Google Scholar 

  14. Bowman BH: Haptoglobin. In Hepatic Plasma Proteins. Edited by Bowman BH. San Diego: Academic Press; 1993:159–167.

    Google Scholar 

  15. Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996, 42:1589–1600.

    CAS  PubMed  Google Scholar 

  16. Asleh R, Marsh S, Shilkrut M, et al.: Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003, 92:1193–1200.

    Article  CAS  PubMed  Google Scholar 

  17. Asleh R, Guetta J, Kalet-Litman S, et al.: Haptoglobin genotype—and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ Res 2005, 96:435–441.

    Article  CAS  PubMed  Google Scholar 

  18. Levy AP, Purushothaman KR, Levy NS, et al.: Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 2007, 101:106–110.

    Article  CAS  PubMed  Google Scholar 

  19. Asleh R, Levy AP: In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 2005, 1:19–28.

    Article  CAS  PubMed  Google Scholar 

  20. • Asleh R, Blum S, Kalet-Litman S, et al.: Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008, 57:2794–2800. This study demonstrates that the Hp 2-2 genotype and diabetes interact to promote HDL dysfunction. It further shows that vitamin E administration improves HDL function in individuals with diabetes carrying the Hp 2-2 genotype.

    Article  CAS  PubMed  Google Scholar 

  21. Schwartz A, Blum S, Asleh R, et al.: Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction. Pharmacogenomics and Personalized Medicine 2009, 2:1–8.

    CAS  Google Scholar 

  22. Costacou T, Ferrell RE, Orchard TJ: Haptoglobin genotype and renal disease progression in type 1 diabetes. Diabetes 2008, 57:1702–1706.

    Article  CAS  PubMed  Google Scholar 

  23. Nakhoul FM, Zoabi R, Kanter Y, et al.: Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001, 44:602–604.

    Article  CAS  PubMed  Google Scholar 

  24. Conway BR, Savage DA, Brady HR, Maxwell AP: Association between haptoglobin gene variants and diabetic nephropathy: haptoglobin polymorphism in nephropathy susceptibility. Nephron Exp Nephrol 2007, 105:e75–e79.

    Article  CAS  PubMed  Google Scholar 

  25. Costacou T, Orchard TJ: Renal hyperfiltration in relation to low renal function and incidence of overt nephropathy among individuals with type 1 diabetes [abstract]. Diabetologia 2009, 52(Suppl 1):S414.

    Google Scholar 

  26. Möllsten A, Lajer M, Jorsal A, Tarnow L: The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes. Mol Genet Metab 2009, 97:80–84.

    Article  PubMed  Google Scholar 

  27. Soedamah-Muthu SS, Chaturvedi N, Witte DR, et al.: Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008, 31:1360–1366.

    Article  CAS  PubMed  Google Scholar 

  28. Zgibor JC, Piatt GA, Ruppert K, et al.: Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care 2006, 29:1860–1865.

    Article  PubMed  Google Scholar 

  29. Gusso S, Hofman P, Lalande S, et al.: Impaired stroke volume and aerobic capacity in female adolescents with type 1 and type 2 diabetes mellitus. Diabetologia 2008, 51:1317–1320.

    Article  CAS  PubMed  Google Scholar 

  30. Mayer-Davis EJ, Ma B, Lawson A, et al.: Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering. Metab Syndr Relat Disord 2009, 7:89–95.

    Article  CAS  PubMed  Google Scholar 

  31. McGill M, Molyneaux L, Twigg SM, Yue DK: The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications 2008, 22:18–23.

    Article  PubMed  Google Scholar 

  32. Thorn LM, Forsblom C, Wadén J, et al.: Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2009, 32:950–952.

    Article  PubMed  Google Scholar 

  33. Guy J, Ogden L, Wadwa RP, et al.: Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care 2009, 32:416–420.

    Article  CAS  PubMed  Google Scholar 

  34. Brock JW, Jenkins AJ, Lyons TJ, et al.: Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res 2008, 49:847–855.

    Article  CAS  PubMed  Google Scholar 

  35. Johansson F, Kramer F, Barnhart S, et al.: Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc Natl Acad Sci U S A 2008, 105:2082–2087.

    Article  CAS  PubMed  Google Scholar 

  36. American Diabetes Association, Bantle JP, Wylie-Rosett J, et al.: Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008, 31(Suppl 1):S61–S78.

    Google Scholar 

  37. Snell-Bergeon JK, Chartier-Logan C, Maahs DM, et al.: Adults with type 1 diabetes eat a high-fat atherogenic diet that is associated with coronary artery calcium. Diabetologia 2009, 52:801–809.

    Article  CAS  PubMed  Google Scholar 

  38. Strychar I, Cohn JS, Renier G, et al.: Effects of a diet higher in carbohydrate/lower in fat versus lower in carbohydrate/higher in monounsaturated fat on postmeal triglyceride concentrations and other cardiovascular risk factors in type 1 diabetes. Diabetes Care 2009, 32:1597–1599.

    Article  CAS  PubMed  Google Scholar 

  39. Hiatt WR: Aspirin for prevention of cardiovascular events. BMJ 2008, 337:a1806.

    Article  PubMed  Google Scholar 

  40. Belch J, MacCuish A, Campbell I, et al.: The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840.

    Article  PubMed  Google Scholar 

  41. Snell-Bergeon JK, Dabelea D, Ogden LG, et al.: Reproductive history and hormonal birth control use are associated with coronary calcium progression in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2008, 93:2142–2148.

    Article  CAS  PubMed  Google Scholar 

  42. Zimmerman MA, Flores SC: Autoimmune-mediated oxidative stress and endothelial dysfunction: implications of accelerated vascular injury in type I diabetes. J Surg Res 2009, 155:173–178.

    Article  CAS  PubMed  Google Scholar 

  43. Nin JW, Ferreira I, Schalkwijk CG, et al.: Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009, 52:705–714.

    Article  CAS  PubMed  Google Scholar 

  44. Astrup AS, Tarnow L, Pietraszek L, et al.: Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008, 31:1170–1176.

    Article  CAS  PubMed  Google Scholar 

  45. Lajer M, Tarnow L, Jorsal A, et al.: Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008, 31:747–752.

    Article  CAS  PubMed  Google Scholar 

  46. Miller RG, Prince CT, Klein R, Orchard TJ: Retinal vessel diameter and the incidence of coronary artery disease in type 1 diabetes. Am J Ophthalmol 2009, 147:653–660.

    Article  PubMed  Google Scholar 

  47. Snell-Bergeon JK, Maahs DM, Ogden LG, et al.: Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009, 11:1–9.

    Article  CAS  PubMed  Google Scholar 

  48. Katakami N, Matsuhisa M, Kaneto H, et al.: Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009, 204:288–292.

    Article  CAS  PubMed  Google Scholar 

  49. Jorsal A, Tarnow L, Flyvbjerg A, et al.: Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008, 51:2100–2107.

    Article  CAS  PubMed  Google Scholar 

  50. Orchard TJ, Olson JC, Erbey JR, et al.: Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003, 26:1374–1379.

    Article  PubMed  Google Scholar 

  51. Lykke JA, Tarnow L, Parving HH, et al.: A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scand J Clin Lab Invest 2008, 68:654–659.

    Article  CAS  PubMed  Google Scholar 

  52. Lacigova S, Bartunek L, Cechurova D, et al.: Influence of cardiovascular autonomic neuropathy on atherogenesis and heart function in patients with type 1 diabetes. Diabetes Res Clin Pract 2009, 83:26–31.

    Article  PubMed  Google Scholar 

  53. Rosengård-Bärlund M, Bernardi L, Fagerudd J, et al.: Early autonomic dysfunction in type 1 diabetes: a reversible disorder? Diabetologia 2009, 52:1164–1172.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Epidemiology, University of Pittsburgh, 3512 Fifth Avenue, Pittsburgh, PA, 15213, USA

    Trevor J. Orchard & Tina Costacou

Authors
  1. Trevor J. Orchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tina Costacou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Trevor J. Orchard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orchard, T.J., Costacou, T. When Are Type 1 Diabetic Patients at Risk for Cardiovascular Disease?. Curr Diab Rep 10, 48–54 (2010). https://doi.org/10.1007/s11892-009-0089-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-009-0089-3

Keywords

Search

Navigation